3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Temozolomide
31
Magnetic Resonance Spectroscopy
31
Specimen Handling
18
Radiation
13
Radiotherapy
12
Biopsy
11
Bevacizumab
11
Nivolumab
9
X-Rays
7
Radiosurgery
7
Nuclear Medicine Department, Hospital
7
Carboplatin
7
Lomustine
6
Cyclophosphamide
6
Vincristine
5
Phantoms, Imaging
5
Cisplatin
5
ulixertinib
4
trametinib
4
pembrolizumab
4
erdafitinib
4
binimetinib
4
abemaciclib
4
Irinotecan
4
Ipilimumab
4
Immunoglobulin G
4
Etoposide
4
Disulfides
4
Aminolevulinic Acid
4
AZD 6244
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
entrectinib
×
CNS
×
30 days
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA